Trial · NCT06259565
Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults
NCT06259565, Phase 3, Recruiting, St. Joseph's Healthcare Hamilton
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults. Trials, record NCT06259565. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06259565
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults
- NCT number
- NCT06259565
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 846 participants, estimated
- Lead sponsor
- St. Joseph's Healthcare Hamilton
- Conditions
- Non-Invasive Ventilation
- Interventions
- Dexmedetomidine, Placebo Control
- First posted
- 2024-02-14
- Last updated
- 2025-09-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | NIV Failure | 28 days | The primary outcome is NIV failure, defined by either mortality or intubation |
| Secondary | Physiologic outcomes: Incidence of delirium | 28 days | Delirium assessed using the ICU-CAM or ICDSC every 12 hours during NIV and daily thereafter until ICU discharge |
| Secondary | Physiologic outcomes: Incidence of agitation | 28 days | Agitation defined as Richmond Agitation Sedation Scale (RASS) ≥2+ during NIV), where RASS scale ranges from -5 (unrousable) to +4 (combative). |
| Secondary | Major morbidity or mortality outcomes: Intubation | 14 days | Intubation |
| Secondary | Major morbidity or mortality outcomes: ICU Mortality | 28 days | ICU mortality |
| Secondary | Major morbidity or mortality outcomes: Hospital Mortality | 90 days | Hospital Mortality |
| Other | Functional Outcome: EQ-5D-5L | 90 days | The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. EQ-5D-5L index scores range from -0.59 to 1, where 1 is the best possible health state |
| Other | Functional Outcome: EQ-VAS | 90 days | The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' and 'The worst health you can image'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. EQ VAS scores range from 0 to 100, where 100 is the best possible health state. |
| Other | Functional Outcome: Clinical Frailty Scale | 90 days | The CFS summarizes the overall level of fitness or frailty of an older adult after they had been evaluated by a clinician. A score from 1 (very fit) to 9 (terminally ill) is given based on the descriptions and pictographs of activity and functional status. |
| Other | Hospital outcomes | 90 days | Hospital Length of Stay (LOS) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06259565
GET https://conductscience.org/api/trials/v1/NCT06259565/registered